03 Profile
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Diabetes
Martin Fussenegger
professor in ETH Zurich's Department of Biosystems Science and Engineering in Basel
press citation on 1 topic since 30 Oct 2026 · last quoted 30 Oct 2026
02 Quoted on · 1 of 29 topics
Martin Fussenegger: key facts
- Kind of voice
- Academic
- Role
- professor in ETH Zurich's Department of Biosystems Science and Engineering in Basel
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 30 Oct 2026
04 The signal · where Martin Fussenegger sits on diabetes
Ranked 45= of 100 voices quoted in the press on diabetes, level with 55 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Douglas TwenefourClinicianHead of Clinical, Diabetes UK11 - 2
Helen KnightRegulatorDirector of Medicines Evaluation, National Institute for Health and Care Excellence (NICE)9 - 3
Parth NarendranAcademicProfessor of Diabetes Medicine; Honorary Consultant Physician (leads the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital Birmingham), University of Birmingham7 - 45=Dr Nomathemba ChandiwanaAcademicChief scientific officer at the Desmond Tutu Health Foundation in South Africa, specialises in obesity and non-communicable diseases (NCDs)1
- 45=Dr Sadia NiaziAcademicSenior Clinical Lecturer in Endodontology, King's College London1
- 45=Martin FusseneggerAcademicprofessor in ETH Zurich's Department of Biosystems Science and Engineering in Basel1
- 45=Sufyan HussainClinicianconsultant diabetes physician at Guy's and St Thomas' NHS Foundation Trust and King's College London1
- 45=Andrea SanabriaClinicianDr, interim director of Public Health1
Showing the leaders and the ranks around 45=, of 100 voices · See every voice on the topic →
05 On the record · press
What Martin Fussenegger has said
- sciencefocus.com1
Where Martin Fussenegger has been quoted
- 01A drug-free treatment for diabetes and obesity is within reach, say experts (and it's not exercise)sciencefocus.com · 30 Oct 2026
Verbatim
“"Our device does something fundamentally different from conventional diabetes treatments [such as insulin and metformin]," said Prof Martin Fussenegger, professor of biotechnology and bioengineering at ETH Zurich and the University of Basel, who co-authored the study.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- First UK patient treated with NICE approved TeplizumabUniversity of Birmingham
- Branding update for insulin pensDiabetes Research & Wellness Foundation
- DRWF Events: Register now for Diabetes: A Whole Life BlueprintDiabetes Research & Wellness Foundation
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.